Insulet Corporation PODD
149.92 USD +3.41 (+2.33%)
Nov 9, 2026, 2:21 PM EST
145.41 Day range 150.38
130.47 52-week range 346.36
- YTD
- -47.26%
- 1 year
- -53.12%
News
benzinga.com Truist Securities Reiterates Hold on Insulet, Raises Price Target to $160 Truist Securities analyst Richard Newitter reiterates Insulet (NASDAQ:PODD) with a Hold and raises the price target from $153 to $160.
benzinga.com Barclays Maintains Equal-Weight on Insulet, Raises Price Target to $165 Barclays analyst Christopher Pasquale maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $150 to $165.
benzinga.com UBS Maintains Neutral on Insulet, Raises Price Target to $171 UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $150 to $171.- benzinga.com JP Morgan Maintains Neutral on Insulet, Raises Price Target to $170 JP Morgan analyst Robbie Marcus maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $152 to $170.
- benzinga.com Citigroup Maintains Neutral on Insulet, Raises Price Target to $170 Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $150 to $170.
- benzinga.com Leerink Partners Maintains Market Perform on Insulet, Raises Price Target to $167 Leerink Partners analyst Mike Kratky maintains Insulet (NASDAQ:PODD) with a Market Perform and raises the price target from $143 to $167.
- benzinga.com RBC Capital Maintains Outperform on Insulet, Raises Price Target to $180 RBC Capital analyst Kendall Au maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $160 to $180.
benzinga.com Bernstein Maintains Outperform on Insulet, Raises Price Target to $200 Bernstein analyst Lee Hambright maintains Insulet (NASDAQ:PODD) with a Outperform and raises the price target from $175 to $200.
benzinga.com Wells Fargo Maintains Equal-Weight on Insulet, Raises Price Target to $172 Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:PODD) with a Equal-Weight and raises the price target from $144 to $172.
benzinga.com Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market Share Insulet stock jumps on strong Q3 results, beating estimates with $842M in revenue, raising its 2026 outlook, and launching a $1B buyback.
marketbeat.com What Insulet (PODD) Said on Its Q3 Earnings Call Insulet NASDAQ: PODD reported third-quarter revenue of $842 million, up 19.2% on a reported basis and 19.6% on a constant-currency basis, as international growth outpaced the company's plans and U.S.…
seekingalpha.com Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript
zacks.com Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
zacks.com Insulet (PODD) Q3 Earnings and Revenues Surpass Estimates Insulet (PODD) came out with quarterly earnings of $1.99 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.24 per share a year ago.
benzinga.com Insulet Q3 2026 Earnings Call Transcript Insulet (NASDAQ:PODD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.46 Est; Raises FY2026 Sales Guidance from $3.250B-$3.304B to $3.277B-$3.304B vs $3.289B Est Insulet (NASDAQ:PODD) FY2026 expected to be more than $6.46 vs $6.46 Est. raises FY2026 sales outlook from $3.250 billion-$3.304 billion to $3.277 billion-$3.304 billion vs $3.289 billion estimate.- benzinga.com Insulet Q3 Adj. EPS $1.99 Beats $1.59 Estimate, Sales $842.000M Beat $832.685M Estimate Insulet (NASDAQ:PODD) reported quarterly earnings of $1.99 per share which beat the analyst consensus estimate of $1.59 by 25.16 percent. This is a 60.48 percent increase over earnings of $1.24 per…
businesswire.com Insulet Reports Third Quarter 2026 Results ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced…
businesswire.com Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will…
defenseworld.net Insulet Corporation $PODD Stock: International Assets Investment Management LLC Boosts Stake International Assets Investment Management LLC grew its position in Insulet Corporation (NASDAQ: PODD) by 61,543.8% during the undefined quarter, according to the company in its most recent…- benzinga.com Jefferies Maintains Buy on Insulet, Lowers Price Target to $190 Jefferies analyst Matthew Taylor maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $275 to $190.
benzinga.com Insulet Reports Q2 2026 Results: Full Earnings Call Transcript Insulet (NASDAQ:PODD) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For…
benzinga.com Barclays Initiates Coverage On Insulet with Equal-Weight Rating, Announces Price Target of $150 Barclays analyst Christopher Pasquale initiates coverage on Insulet (NASDAQ:PODD) with a Equal-Weight rating and announces Price Target of $150.
benzinga.com FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.- benzinga.com Canaccord Genuity Maintains Buy on Insulet, Lowers Price Target to $179 Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $249 to $179.
benzinga.com Leerink Partners Downgrades Insulet to Market Perform, Lowers Price Target to $145 Leerink Partners analyst Mike Kratky downgrades Insulet (NASDAQ:PODD) from Outperform to Market Perform and lowers the price target from $247 to $145.- benzinga.com TD Cowen Maintains Hold on Insulet, Lowers Price Target to $144 TD Cowen analyst Mathew Blackman maintains Insulet (NASDAQ:PODD) with a Hold and lowers the price target from $294 to $144.
- benzinga.com UBS Maintains Neutral on Insulet, Lowers Price Target to $150 UBS analyst Patrick Wood maintains Insulet (NASDAQ:PODD) with a Neutral and lowers the price target from $174 to $150.
- benzinga.com RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $160 RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $245 to $160.
- benzinga.com Bernstein Maintains Outperform on Insulet, Lowers Price Target to $175 Bernstein analyst Lee Hambright maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $200 to $175.
benzinga.com Benchmark Maintains Buy on Insulet, Lowers Price Target to $185 Benchmark analyst Bruce D. Jackson maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $185.- benzinga.com Stifel Maintains Buy on Insulet, Lowers Price Target to $180 Stifel analyst Jonathan Block maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $225 to $180.
benzinga.com Paycom Software To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Thursday Analysts changed outlook on top names: JP Morgan cut price target for Insulet, HC Wainwright slashed EyePoint's target, Goldman cut Sunrun's, B of A lowered Coupang's, BTIG cut Klaviyo's, Jefferies…
benzinga.com This HubSpot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday Top Wall Street analysts changed outlook on top names. See all changes on analyst ratings page. HUBS, PODD, FRPT, WTTR, REXR downgraded.
benzinga.com These Analysts Slash Their Forecasts On Insulet After Q2 Results Insulet Corp. (NASDAQ:PODD) reported strong Q2 earnings but lowered revenue outlook for 2021. Analysts downgraded stock and lowered price targets.- benzinga.com Wells Fargo Downgrades Insulet to Equal-Weight, Lowers Price Target to $144 Wells Fargo analyst Lawrence Biegelsen downgrades Insulet (NASDAQ:PODD) from Overweight to Equal-Weight and lowers the price target from $255 to $144.
- benzinga.com JP Morgan Downgrades Insulet to Neutral, Lowers Price Target to $152 JP Morgan analyst Robbie Marcus downgrades Insulet (NASDAQ:PODD) from Overweight to Neutral and lowers the price target from $275 to $152.
- benzinga.com Truist Securities Downgrades Insulet to Hold, Lowers Price Target to $153 Truist Securities analyst Richard Newitter downgrades Insulet (NASDAQ:PODD) from Buy to Hold and lowers the price target from $210 to $153.
benzinga.com Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool inflation fears.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX)…
benzinga.com Omnipod Sales Soar, But Insulet's Outlook Cut Sparks Stock Selloff Insulet (PODD) stock falls despite beating Q2 earnings as the company lowers its full-year 2026 revenue guidance. Get details here.- benzinga.com Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.43 Est; Lowers FY2026 Sales Guidance from $3.277B-$3.331B to $3.250B-$3.304B vs $3.321B Est Insulet (NASDAQ:PODD) FY2026 expected to be more than $6.46 vs $6.43 Est. lowers FY2026 sales outlook from $3.277 billion-$3.331 billion to $3.250 billion-$3.304 billion vs $3.321 billion estimate.
- benzinga.com Insulet Q2 Adj. EPS $1.66 Beats $1.45 Estimate, Sales $801.700M Beat $787.228M Estimate Insulet (NASDAQ:PODD) reported quarterly earnings of $1.66 per share which beat the analyst consensus estimate of $1.45 by 14.48 percent. This is a 41.88 percent increase over earnings of $1.17 per…
- benzinga.com Insulet Corporation Partners With Calm To Provide Free Mindfulness Resources Addressing Anxiety And Burnout Among People Living With Diabetes The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise,…
- benzinga.com Truist Securities Maintains Buy on Insulet, Lowers Price Target to $210 Truist Securities analyst Richard Newitter maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $219 to $210.
- benzinga.com RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $245 RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $280 to $245.
- benzinga.com Stifel Maintains Buy on Insulet, Lowers Price Target to $225 Stifel analyst Jonathan Block maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $225.
- benzinga.com Citigroup Maintains Neutral on Insulet, Raises Price Target to $172 Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $165 to $172.
benzinga.com FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports FDA classified Insulet's Omnipod pod recall as Class I after reports of insulin under-delivery linked to 24 serious injuries.- benzinga.com Evercore ISI Group Maintains Outperform on Insulet, Lowers Price Target to $180 Evercore ISI Group analyst Daniel Markowitz maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $200 to $180.